RCC patients with high expression of LATS1 or LATS2 have significantly longer overall survival (OS) and disease-free survival (DFS) than those with low expression of LATS1/2 (Zhang et al., 2020). This evidence concerns the gene LATS1 and renal cell carcinoma.